Publication: Retrospective study of the adverse events of the treatment for an acute attack of neuromyelitis optica spectrum disorder
Issued Date
2019-01-01
Resource Type
ISSN
17449987
17449979
17449979
Other identifier(s)
2-s2.0-85076930194
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Therapeutic Apheresis and Dialysis. (2019)
Suggested Citation
Titinan Veerachit-O-larn, Sasitorn Siritho, Naraporn Prayoonwiwat Retrospective study of the adverse events of the treatment for an acute attack of neuromyelitis optica spectrum disorder. Therapeutic Apheresis and Dialysis. (2019). doi:10.1111/1744-9987.13456 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/52204
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Retrospective study of the adverse events of the treatment for an acute attack of neuromyelitis optica spectrum disorder
Abstract
© 2019 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy Intravenous methylprednisolone (IVMP) is an initially recommended therapy for an acute attack of neuromyelitis optica spectrum disorder (NMOSD). For those who do not respond to steroid treatment, plasma exchange (PLEX) is generally added-on. We evaluated adverse events of an acute treatment in NMOSD patients in a university-based hospital during January 2009 and December 2017. Ninety-seven patients with 177 attacks were collected. The therapy included IVMP alone (123 events, 62.4%), IVMP followed by PLEX (46 events, 23.4%) and, PLEX alone (8 events, 4.5%). Adverse events occurred in 36.7% of the IVMP group and 61.1% of the PLEX group. The most common adverse event was hyperglycemia (43.5%) followed by infection (29%) in the former and hypocalcemia (63.6%) followed by hypofibrinogen (42.4%), hypotension (30.3%), and infection (21.2%) in the latter. One severe adverse event was documented in the IVMP group and 13 events in the PLEX groups, nevertheless, all were manageable.